Immanuel
announced that she has been cleared of the allegation in a post on her Facebook
page on Wednesday.
Controversial
US-based physician, Dr Stella Immanuel, is rejoicing over the dismissal of the
complaints against her following her claim that hydroxychloroquine can cure
COVID-19 by the Texas Medical Board.
She also
attached the letter of clearance from the Texas Medical Board which she asked
her haters to “read and weep.”
She said,
”Texas medical board dismisses the complaint against me. The haters have been
defeated and God has shown Himself as my protector and defender. God bless TMB,
God bless Texas, God bless America. Good will win.
American will win. Haters
read and weep.”
In the
letter, the Board indicated that the investigation was dismissed because there
was insufficient evidence to prove that she violated Medical Practices Act.
“As such,
this complaint has been dismissed without prejudice. No further action will be
taken concerning this complaint,” the Board said in the letter.
Immanuel had
early August through a tweet announced that the Texas Medical Board had opened
an investigation into her claim that the anti-malaria drug can cure COVID-19.
This followed
an early warning by the Board that it will take action against any complaint
about false, misleading or deceptive advertising for COVID-19 cure under its
standard enforcement process.
In the tweet
confirming that the Board has begun investigating her, the Huston based doctor
had also solicited for donations to fund her legal efforts.
Immanuel
attracted global attention in July 2020 when a video of her touting
hydroxychloroquine as a cure for Covid-19 went viral taken in company of other
medical doctors went viral.
The letter by
Texas Medical Board clearing Dr Immmanuel
“If they put
everybody on hydroxychloroquine it would stop COVID-19 in its tracks in 30
days,” she said in the video recorded at a news conference.
The video
went viral after President Donald Trump who had also touted hydroxychloroquine
as a cure for COVID-19 shared it on Twitter.
No comments:
Post a Comment